By Joshua Kirby

 

Roche Holding AG said Friday that it received an approval recommendation from a European Medicines Agency committee for Evrysdi, its spinal muscular atrophy treatment.

The Swiss pharmaceutical company said the EMA's committee for Medicinal Products for Human Use recommended the approval of Evrysdi in patients aged two months and older diagnosed with SMA of various types.

The recommendation was made under the accelerated assessment pathway for medicines considered to be of major public interest for public health, Roche said. A final decision from the EMA on the use of the treatment in the European Union is expected within the next two months, it added.

 

Write to Joshua Kirby at joshua.kirby@dowjones.com; @joshualeokirby

 

(END) Dow Jones Newswires

February 26, 2021 06:58 ET (11:58 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.